+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Familial Adenomatous Polyposis - Pipeline Review, H1 2019

  • ID: 4760840
  • Drug Pipelines
  • March 2019
  • Region: Global
  • 61 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4

FEATURED COMPANIES

  • Adhera Therapeutics
  • Cellix Bio Pvt Ltd
  • Johnson & Johnson
  • MORE
Familial Adenomatous Polyposis - Pipeline Review, H1 2019

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Familial Adenomatous Polyposis - Pipeline Review, H1 2019, provides an overview of the Familial Adenomatous Polyposis (Genetic Disorders) pipeline landscape.

Familial adenomatous polyposis (FAP) or classic FAP is a genetic condition that causes extra tissue (polyps) to form in large intestine and rectum. It is caused by germline mutations in the APC gene. Symptoms include blood or mucus in the stools, diarrhea or constipation, weight loss due to unknown reason and abdominal pain. Treatment includes surgery and medications (NSAIDs).

Report Highlights

This latest pipeline guide Familial Adenomatous Polyposis - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Familial Adenomatous Polyposis (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Familial Adenomatous Polyposis (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Familial Adenomatous Polyposis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase I, Preclinical, Discovery and Unknown stages are 2, 3, 5, 2 and 1 respectively.

Familial Adenomatous Polyposis (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from 's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Familial Adenomatous Polyposis (Genetic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Familial Adenomatous Polyposis (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Familial Adenomatous Polyposis (Genetic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Familial Adenomatous Polyposis (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Familial Adenomatous Polyposis (Genetic Disorders)
Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Familial Adenomatous Polyposis (Genetic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Familial Adenomatous Polyposis (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Adhera Therapeutics
  • Cellix Bio Pvt Ltd
  • Johnson & Johnson
  • MORE
Introduction

Report Coverage

Familial Adenomatous Polyposis - Overview

Familial Adenomatous Polyposis - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Familial Adenomatous Polyposis - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Familial Adenomatous Polyposis - Companies Involved in Therapeutics Development

Adhera Therapeutics

Cancer Prevention Pharmaceuticals Inc

Cellix Bio Pvt Ltd

Johnson & Johnson

Recursion Pharmaceuticals Inc

Thetis Pharmaceuticals LLC

Familial Adenomatous Polyposis - Drug Profiles

(celecoxib + lisinopril) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(eflornithine hydrochloride + sulindac) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CLX-157 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FAPXIL SR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy for Familial Adenomatous Polyposis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

guselkumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

icosapent ethyl - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

M-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pyrvinium pamoate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RMX-1002 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sirolimus - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Familial Adenomatous Polyposis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TP-252 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Familial Adenomatous Polyposis - Dormant Projects

Familial Adenomatous Polyposis - Discontinued Products

Familial Adenomatous Polyposis - Product Development Milestones

Featured News & Press Releases

Feb 26, 2019: Rapamycin Holdings rebrands to Emtora Biosciences as new leadership focuses company on next steps

Dec 10, 2018: Cancer Prevention Pharmaceuticals Announces Last Patient Completes Phase 3 Trial Protocol of CPP-1X/sul for Familial Adenomatous Polyposis

Feb 22, 2018: Cancer Prevention Pharmaceuticals Appoints Willene Brondum Associate Vice President of Regulatory Affairs and Quality Assurance

Nov 21, 2017: Cancer Prevention Pharmaceuticals to Present at the 29th Annual Piper Jaffray Healthcare Conference

Sep 18, 2017: FDA Grants “Fast Track” Status to Cancer Prevention Pharmaceuticals’ Lead Drug CPP-1X/sul for Treatment of Familial Adenomatous Polyposis

Jun 12, 2017: Independent Data Monitoring Committee Recommends Continuation of Cancer Prevention Pharmaceuticals’ Phase 3 Trial for Familial Adenomatous Polyposis Patients

Mar 29, 2017: Marina Biotech to Present Data on IT-102 at 2017 American Association for Cancer Research Annual Meeting

Apr 14, 2016: Thetis Pharmaceuticals to Present at the World Orphan Drug Congress on TP-252, an Investigational Drug for Familial Adenomatous Polyposis

Apr 04, 2016: Cancer Prevention Pharmaceuticals Completes Target Enrollment in Pivotal Phase 3 Clinical Trial Evaluating CPP-1X/sulindac in Patients with Familial Adenomatous Polyposis

Jan 27, 2016: Thetis Pharmaceuticals Awarded Key Patent for TP-252

Jan 19, 2016: Thetis Receives Orphan Drug Designation for TP-252 in Familial Adenomatous Polyposis

Oct 15, 2015: Thetis Pharmaceuticals Presents at BIO Investor Forum in San Francisco

Aug 04, 2015: Thetis Receives Notice of Allowance for Patent Covering Pharmaceutical Composition of Novel Mineral Amino Acid Derivative TP-252

Dec 05, 2013: Phase III Familial Adenomatous Polyposis Trial Now Open for Enrollment

Dec 08, 2011: S.L.A. Pharma Announces Plans For Alfa Phase III Orphan Drug Program For Familial Adenomatous Polyposis

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Familial Adenomatous Polyposis, H1 2019

Number of Products under Development by Companies, H1 2019

Products under Development by Companies, H1 2019

Number of Products by Stage and Target, H1 2019

Number of Products by Stage and Mechanism of Action, H1 2019

Number of Products by Stage and Route of Administration, H1 2019

Number of Products by Stage and Molecule Type, H1 2019

Familial Adenomatous Polyposis - Pipeline by Adhera Therapeutics, H1 2019

Familial Adenomatous Polyposis - Pipeline by Cancer Prevention Pharmaceuticals Inc, H1 2019

Familial Adenomatous Polyposis - Pipeline by Cellix Bio Pvt Ltd, H1 2019

Familial Adenomatous Polyposis - Pipeline by Johnson & Johnson, H1 2019

Familial Adenomatous Polyposis - Pipeline by Recursion Pharmaceuticals Inc, H1 2019

Familial Adenomatous Polyposis - Pipeline by Thetis Pharmaceuticals LLC, H1 2019

Familial Adenomatous Polyposis - Dormant Projects, H1 2019

Familial Adenomatous Polyposis - Discontinued Products, H1 2019

List of Figures

Number of Products under Development for Familial Adenomatous Polyposis, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products by Targets, H1 2019

Number of Products by Stage and Targets, H1 2019

Number of Products by Mechanism of Actions, H1 2019

Number of Products by Stage and Mechanism of Actions, H1 2019

Number of Products by Routes of Administration, H1 2019

Number of Products by Stage and Routes of Administration, H1 2019

Number of Products by Molecule Types, H1 2019

Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Adhera Therapeutics
  • Cancer Prevention Pharmaceuticals Inc
  • Cellix Bio Pvt Ltd
  • Johnson & Johnson
  • Recursion Pharmaceuticals Inc
  • Thetis Pharmaceuticals LLC
Note: Product cover images may vary from those shown
Adroll
adroll